July 20 (Reuters) - Mauna Kea Technologies SAS
MKEA.PA :
* MAUNA KEA TECHNOLOGIES REPORTS SECOND QUARTER AND FIRST
HALF
2023 REVENUE
* MAUNA KEA TECHNOLOGIES SAS Q2 SALES EUR 2.68 MILLION
* REVENUE UP 77% IN Q2 2023DRIVEN BY U.S. SALES GROWTH AND
LICENSING FEE INCOME FROM J.V. WITH TASLY PHARMACEUTICAL
* IN FIRST HALF OF 2023, TOTAL SALES REACHED EUR 6,848K, UP
+102%
VERSUS PRIOR YEAR
* WE ARE EXPLORING AN EXPANDING NUMBER OF STRATEGIC
PARTNERSHIP
OPPORTUNITIES, WHERE WE SEE POTENTIAL TO ACCELERATE ADOPTION OF
CELLVIZIO IN NOVEL INDICATIONS
Source text for Eikon: ID:nBw2TmkD2a
Further company coverage: MKEA.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))